New The Lancet Meta-Analysis by #NelsonWang Brigham and Women's Hospital HF Fellow What is the expected BP lowering with various antihypertensive regimens? Robust model derived from n=104,176 pts across 484 RCTs Terrific user-friendly tool: bpmodel.org thelancet.com/journals/lance…

Muy buena herramienta para estimar cuanto bajaremos la TA a nuestro paciente con el tratamiento antiHTA que le pongamos!!.. así es más fácil y rápido llegar a objetivos 👏👏👏👏

Incredible trifecta by #JohnOstrominski in JACC Journals w #ESCCongress John is a one-of-a-kind talent, blending his joint CV & obesity fellowships, to lead a career in #CKM investigation. One to watch! 🚀 jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.…

La evaluación del CC o del WHtR identifica una cantidad sustancial de individuos con obesidad abdominal a pesar de tener un IMC <30 kg/m2 y puede mejorar la estratificación del riesgo más allá del IMC solo en la ICmrEF/ICpEF. jacc.org/doi/10.1016/j.…

Hoy en el #BlogdeMateu un tema de rabiosa actualidad 📍 ¿Qué hacemos, entonces, con los betabloqueantes? Resumen del Congreso ESC 2025 ✒️Comentario del Dr. Francisco M. Adan Gil (Fran Adán) redgedaps.blogspot.com/2025/09/que-ha…

Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes Use of “four pillars” of CKD therapy, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitor, nonsteroidal mineralocorticoid

New content online: Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors bit.ly/4nw63L4

Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021 Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021 Muthu Vaduganathan Gregg Fonarow MD Steve Greene HF Collaboratory Andrew J Sauer MD

❗️Higher dose GLP-1…. Worth the STEP UP?❗️ Once-weekly semaglutide 7·2 mg in adults with obesity 🔸7.2mg vs 2.4mg vs placebo 🔹mean age 47yrs, mean BMI 39.9 🔸-18.7% vs -15.6% vs -3.9% change in body weight 🔹almost half on 7.2mg achieved 20% weight loss 🔸5.4% permanent,

#easd2025 Remisión de la DM2? Quizás mejor remisión funcional...reversión fisiopatologica y cómo conseguirlo!!!...La clave: tto intensivo y precoz para preservar la función de la célula beta

#EASD2025 Hacer ejercicio moderado a vigoroso por la tarde-noche mejora el perfil glucemico y previene la DM2

#EASD2025 Glucocorticoides aumenta riesgo de DM2 dosis dependiente vía sistémica o tópica. Vía inhalada, ocular u otica no aumenta riesgo.

#EASD2025 Hacer ejercicio moderado a vigoroso por la tarde-noche mejora el perfil glucemico y previene la DM2

Phase 3 trial just published in NEJM for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an average 11.2% weight loss, with 36% losing at least 15% and 18% losing at least 20% of their body weight. Cardiometabolic markers also improved.

25mg oral semaglutide for #weightloss #obesity nejm.org/doi/full/10.10…

🆕 American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update AACE endocrinepractice.org/article/S1530-… 

Hyperkalaemia affects 6–10% of patients globally, with higher prevalence in those with CKD, heart failure, and diabetes, especially those on RAAS inhibitors. Read a consensus statement on management: ow.ly/n9ez50WTxfE #Hyperkalaemia #CardioRenalCare

Glucagon-like peptide-1 receptor agonists across the cardiovascular-kidney-metabolic spectrum: One size does not fit all onlinelibrary.wiley.com/doi/10.1002/ej… #CKM #GLP1RA #EJHF EJHF Editor-in-Chief European Society of Cardiology Journals

Al inicio del ensayo clínico CONFIDENCE el 22% consumía algún aGLP1, esto no tuvo impacto sobre la gran reducción en albuminuria (↓52%) que se observó con el inicio de la combinación simultánea de finerenona + empagliflozina Diabetes Care 2025 doi.org/10.2337/dc25-1…

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology | JACC jacc.org/doi/10.1016/j.… SABOURETCardiologist Juan Torres Macho Juan Torres Macho Marcos Gamboa Chema Fernandez Call to action: inflammation and CVD